Noven to Present at Banc of America Securities Specialty Pharmaceuticals Conference
Posted on: Monday, 25 July 2005, 09:01 CDT
Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that company representatives are scheduled to present at the Banc of America Securities Specialty Pharmaceuticals Conference in Southampton, New York, on Thursday, July 28, 2005 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be accessible to the public at http://www.noven.com and a rebroadcast will be available thereafter at the same site.
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven's prescription patches are sold in over 30 countries, and a range of new patches are being investigated and developed in collaboration with Novartis Pharma AG, Shire Pharmaceuticals Group plc, P&G Pharmaceuticals, Endo Pharmaceuticals Inc. and others. Noven is committed to expanding the universe of available transdermal therapies for the benefit of patients, partners and shareholders. See http://www.noven.com for additional information.
Source: Business Wire
Related Articles
- Noven Announces 2008 Third Quarter Financial Results
- Future Drug Pipelines and Prospects Revealed for RNAi Therapeutics
- Noven Announces 2008 Second Quarter Financial Results
- Noven Announces Triggering of $25 Million Daytrana(R) Sales Milestone
- Noven Announces Final FDA Approval of Stavzor(TM) for the Treatment of Bipolar Disorder, Seizures and Migraine Headaches
- Banner Pharmacaps Receives FDA Approval for Valproic Acid Delayed Release Softgel Capsules
- Learn About the Leading Drug Delivery Companies and Technologies: Competitive Landscape, Company Profiles and Technological Developments
- Noven Names Steven M. Dinh Vice President and Chief Scientific Officer
- Neil Jones to Step Down As Noven's Vice President of Marketing & Sales
- Shire and Noven Announce Positive Clinical Data for Transdermal ADHD Treatment
User Comments (0)

RSS Feeds